Article
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.
Blood advances - 25 Feb 2025
Luque Paz Damien, Gagelmann Nico, Benajiba Lina, Riou Jérémie, Salit Rachel, Orvain Corentin, Schroeder Thomas, Bories Claire, Gurnari Carmelo, Badbaran Anita, Boyer Françoise, Pagliuca Simona, Rautenberg Christina, Tavitian Suzanne, Pangiota Victoria, Ianotto Jean-Christophe, Thol Felicitas, Cayssials Emilie, Heuser Michael, Rubio Marie-Thérèse, Cassinat Bruno, Daltro de Oliveira Rafael, Sauter Craig, Maciejewski Jaroslaw P, Reinhardt Hans Christian, Scott Bart L, Ugo Valérie, Kröger Nicolaus, Kiladjian Jean-Jacques, Robin Marie
Abstract excerpt
ABSTRACT: The aim of our study was to analyze the potential survival benefit associated with hematopoietic stem cell transplantation (HSCT) according to clinicobiological scores, which incorporate mutation-enhanced international prognostic score system (MIPSS) to facilitate decision-making in this context. One transplant (n = 241) and 1 nontransplant cohort (n = 239) were used to test the hypothesis that patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
